Human RCTPubMed ID: 35453136·2022

SURPASS-5: Tirzepatide in East Asian Populations

Ji L, Onishi Y, Ahn CW, et al.

Lancet Diabetes and Endocrinology, 2022 · n = 743

Key finding

Tirzepatide 15mg reduced HbA1c by 2.3% in East Asian population (similar to global trials), with weight loss of 8.4kg versus 2.0kg placebo.

Summary

Phase 3 trial evaluating tirzepatide efficacy and safety in East Asian patients with type 2 diabetes.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot